rebound symptoms on day 10. congestion, cough, fatigue, stomach issues; rebound symptoms on day 10. congestion, cough, fatigue, stomach issues; rebound symptoms on day 10. congestion, cough, fatigue, stomach issues; rebound symptoms on day 10. congestion, cough, fatigue, stomach issues; rebound symptoms on day 10. congestion, cough, fatigue, stomach issues; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 03-Jun-2022 and was forwarded to Moderna on 03-Jun-2022.    This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), NASAL CONGESTION (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), COUGH (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), ABDOMINAL DISCOMFORT (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues) and FATIGUE (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026D214, 001CZ1A and 008B21A) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Depression, Vitiligo, Hypothyroidism, Drug allergy (lamotrigine) and Hay fever. Concomitant products included FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), DULOXETINE HYDROCHLORIDE (CYMBALTA) and FISH OIL for an unknown indication.   On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 01-Jun-2022 at 4:00 PM, the patient experienced COVID-19 (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), NASAL CONGESTION (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), COUGH (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), ABDOMINAL DISCOMFORT (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues) and FATIGUE (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues). At the time of the report, COVID-19 (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), NASAL CONGESTION (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), COUGH (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues), ABDOMINAL DISCOMFORT (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues) and FATIGUE (rebound symptoms on day 10. congestion, cough, fatigue, stomach issues) had not resolved.            Patient was taking other medications/products within 2 weeks of starting COVID-19 treatment The patient previously received a COVID-19 Vaccine. No treatment drugs were reported Device date was reported as 02-Jun-2022 COMPANY COMMENT: This is an spontaneous case concerning an 47-year-old female patient with  medical history of Depression, Vitiligo, Hypothyroidism, Drug allergy, Hay fever concomitant products included FLUTICASONE, DULOXETINE and FISH OIL for an unknown indication, RITONAVIR for COVID-19 treatment from 25 to 29, May, 2022 who experienced the unexpected events of COVID-19, NASAL CONGESTION, COUGH, FATIGUE  and ABDOMINAL DISCOMFORT 218 days after 3rd dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning an 47-year-old female patient with  medical history of Depression, Vitiligo, Hypothyroidism, Drug allergy, Hay fever concomitant products included FLUTICASONE, DULOXETINE and FISH OIL for an unknown indication, RITONAVIR for COVID-19 treatment from 25 to 29, May, 2022 who experienced the unexpected events of COVID-19, NASAL CONGESTION, COUGH, FATIGUE  and ABDOMINAL DISCOMFORT 218 days after 3rd dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.